Dual-colour HER2/Chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples

Journal of Clinical Pathology

Volumn 64, Issue 10, 2011, Pages 880-883

  Yan, Benedict ^a   Yau, Ee Xuan ^b   Choo, Shoa Nian ^a   Ong, Chee Wee ^b   Yong, Kol Jia ^b   Pang, Brendan ^a   Salto Tellez, Manuel ^b,c  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; CANCER SURGERY; CHROMOGENIC IN SITU HYBRIDISATION; CHROMOSOME 17; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENETIC HETEROGENEITY; GENOME; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; PRIORITY JOURNAL; STOMACH CANCER; TUMOR BIOPSY;

BIOPSY; CHI-SQUARE DISTRIBUTION; CHROMOSOMES, HUMAN, PAIR 17; FALSE NEGATIVE REACTIONS; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN SITU HYBRIDIZATION, FLUORESCENCE; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; SINGAPORE; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 80053201474     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2011-200009     Document Type: Article

References (7)

1. Bang YJ, van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97.
2. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45. (Pubitemid 350003059)
3. Yan B, Yau EX, Bte Omar SS, et al. A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol 2010;63:839-42.
4. Grabsch H, Sivakumar S, Gray S, et al. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic valuedconclusions from 924 cases of two independent series. Cell Oncol 2010;32:57-65.
5. Marx AH, Tharun L, Muth J, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2009;40:769-77.
6. Lambros MB, Natrajan R, Reis-Filho JS. Chromogenic and fluorescent in situ hybridization in breast cancer. Hum Pathol 2007;38:1105-22. (Pubitemid 47058171)
7. Gruver AM, Peerwani Z, Tubbs RR. Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma. J Clin Pathol 2010;63:210-19.